{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:44:30Z","timestamp":1786729470669,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40121-026-01408-2","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:31:59Z","timestamp":1783503119000},"page":"2439-2454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Virologically Suppressed People with HIV on Any Antiretroviral Therapy Regimen: The Retrospective ESSENTIAL Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-3028","authenticated-orcid":false,"given":"Maria Vittoria","family":"Cossu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5901-6742","authenticated-orcid":false,"given":"Davide","family":"Moschese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2317-6984","authenticated-orcid":false,"given":"Maddalena","family":"Matone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5186-6310","authenticated-orcid":false,"given":"Letizia","family":"Oreni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2081-174X","authenticated-orcid":false,"given":"Giorgia","family":"Carrozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8101","authenticated-orcid":false,"given":"Andrea","family":"Poloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1498-3250","authenticated-orcid":false,"given":"Giacomo","family":"Pozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Forcina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4922-6495","authenticated-orcid":false,"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-3049","authenticated-orcid":false,"given":"Agostino","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4289","authenticated-orcid":false,"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-4794","authenticated-orcid":false,"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"6","key":"1408_CR1","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389\u2013400. https:\/\/doi.org\/10.1016\/S2352-3018(20)30099-0.","journal-title":"Lancet HIV"},{"issue":"7","key":"1408_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2024 recommendations of the international antiviral society\u2013USA Panel. JAMA. 2025;333(7):609\u201328. https:\/\/doi.org\/10.1001\/jama.2024.24543.","journal-title":"JAMA"},{"key":"1408_CR3","unstructured":"European AIDS Clinical Society (EACS). Guidelines Version 13.0 \u2013 October 2025. Disponibile su:\u00a0https:\/\/www.eacsociety.org"},{"issue":"12","key":"1408_CR4","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086\u201397. https:\/\/doi.org\/10.1128\/AAC.01474-16.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"1408_CR5","first-page":"127","volume":"31","author":"AMJ Wensing","year":"2023","unstructured":"Wensing AMJ, Calvez V, G\u00fcnthard HF, et al. Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2023;31(4):127\u201343.","journal-title":"Top Antivir Med"},{"issue":"7","key":"1408_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/hiv.13089","volume":"22","author":"C Orkin","year":"2021","unstructured":"Orkin C, Squires KE, Molina JM, et al. Long-term efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in adults with HIV-1: Week 144 results from randomized clinical trials. HIV Med. 2021;22(7):623\u201332. https:\/\/doi.org\/10.1111\/hiv.13089.","journal-title":"HIV Med"},{"issue":"5","key":"1408_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/jac\/dkac021","volume":"77","author":"L Taramasso","year":"2022","unstructured":"Taramasso L, Ricci E, Menzaghi B, et al. Durability, safety, and metabolic impact of bictegravir\/emtricitabine\/tenofovir alafenamide in a real-world cohort: Results from the ICONA Foundation Study. J Antimicrob Chemother. 2022;77(5):1493\u2013501. https:\/\/doi.org\/10.1093\/jac\/dkac021.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1408_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/QAD.0000000000002488","volume":"34","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ait-Khaled M, Johnson M, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed adults: Week-96 results of the randomized, double-blind GS-US-380\u20131844 study. AIDS. 2020;34(7):953\u201363. https:\/\/doi.org\/10.1097\/QAD.0000000000002488.","journal-title":"AIDS."},{"issue":"6","key":"1408_CR9","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1093\/cid\/ciac358","volume":"76","author":"C Kityo","year":"2023","unstructured":"Kityo C, Hagins DP, Koenig E, et al. Switching from rilpivirine\/emtricitabine\/tenofovir alafenamide to bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed adults living with HIV-1. Clin Infect Dis. 2023;76(6):e450\u20138. https:\/\/doi.org\/10.1093\/cid\/ciac358.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1408_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, De Wit S, Podzamczer D, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world results from the BICSTaR cohort. HIV Med. 2024;25(4):440\u201353. https:\/\/doi.org\/10.1111\/hiv.13593.","journal-title":"HIV Med"},{"issue":"7","key":"1408_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267\u201374. https:\/\/doi.org\/10.1093\/cid\/ciz407.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1408_CR12","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","volume":"71","author":"JE Lake","year":"2020","unstructured":"Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor\u2013based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471\u20137. https:\/\/doi.org\/10.1093\/cid\/ciaa177.","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01408-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:24:14Z","timestamp":1786728254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01408-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01408-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maria Vittoria Cossu reports payment or honoraria for lectures, presentations, or education events from Gilead and ViiV; Davide Moschese reports payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or education events from Gilead and ViiV; Cristina Gervasoni reports personal fees from MSD, ViiV, Gilead, and Janssen-Cilag; Agostino Riva reports payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or education events from Gilead and ViiV; Andrea Giacomelli reports consulting fees from Mylan and Janssen-Cilag; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Gilead and ViiV; payment for expert testimony from Jansen; support for attending meetings and\/or travel from Gilead, ViiV, and MSD; Andrea Gori reports grants or contracts from ViiV, Bristol Myers Squibb, and Gilead; consulting fees from ViiV, Gilead, Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, and Novartis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ViiV, Gilead, Janssen-Cilag, Merck Sharp & Dohme, Bristol Myers Squibb, Pfizer, and Novartis; support for attending meetings and\/or travel from ViiV, Gilead, Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, and Novartis. Maddalena Matone, Letizia Oreni, Giorgia Carrozzo, Andrea Poloni, and Giacomo Pozza have nothing to disclose. Laura Albini and Gabriele Forcina are employees of, and hold stock in, Gilead Sciences. Role of sponsor: The study protocol was developed by the sponsor and submitted to the Ethics Committee. Data were collected as part of routine clinical practice and extracted from the institutional database (dbSacco). Data extraction and statistical analyses were performed exclusively by the investigators. The manuscript was drafted by the authors. The sponsor was given the opportunity to review the manuscript for accuracy prior to submission but had no role in data analysis, interpretation of the results, or the decision to submit the manuscript for publication.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the local Ethics Committee (protocol no. CET 256\u20132024). Given the retrospective design and the use of anonymised data, the requirement for informed consent was waived. Patient consent was waived due to the retrospective nature of the study and anonymised data collection.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}